(b) Yes, Sir.

(i) Re-endorsement for Baralgan Ketone, Frusemide and Control Serum for Tripartigen plates contained the condition that 50% of actual production beyond the existing licensed capacity would be made available to the non associated formulators. Re-endorsement for Glybenclamide, in addition to above condition contained the condition that the company shall be required to export 20 per cent of actual production beyond the existing capacity (200 Kgs) in terms of bulk drug or the formulations or combination of both and the company shall not be allowed to import this bulk drug against the REP licences earned through such exports.

Statement

Sl. No.	Name of the bulk drug	Capacity (Tonnes)	Stage of manufacture as reported by the company
1	Fenbendazole	3.500	Basic
2	Benzocaine	2 000	Basic
3	Para-Amino Benzoic Acid	1.200	Basic
4	Isopropyl Antipyrine	30.000	Basic
5	Prenylamine Lactate	8 000	Basic
6	Sodium Salt of N-4 Methylbenzene Sulfonyl Carbamic Acid Methoxyethyl Ester	2.000	Basic
7	Buclosamide	1.070	Basic

Show cause notice to M/s. Glaxo Lab.

2182. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 183 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) when was the show cause notice issued to M|s Glaxo Lab. in regard to unauthorised installation of plant and machinery and when was their explanation received;

(b) what are the reasons for the delay for final decision on the issue;

(c) whether it is a fact that show cause notice was issued on the findings of technical team who made on the spot verification;

(d) if so, what are the details of the findings;

(e) whether it is a fact that unauthorised installation of plant and machinery was made to overproduce those drugs where company is overcharging the prices; and

(f) if so, names of these drugs where company exceeded the permitted capacity along with the licensed capacity and production of drugs during the last three years, year-wise as well as the price fixed for each drug by Government and the price charged by the company?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) A show cause notice was issued to M|s Glaxo Laboratories on the 10th of September, 1984. Their explanation was received in December, 1984.

(b) to (d) No final decision has been taken on the findings of the technical team and the reply of the company, as a policy decision is required to be taken on all such similar cases.

(e) to (f) The requisite information has already been furnished in reply to Rajya Sabha Unstarred Question No. 161 dt. 18.11.1985.

Higher mark up on medicines

2183. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news item captioned "Higher mark up in new Policy likely", which appeared in 'the Economic Times' on 22nd November, 1985;

(b) if so, whether there is any proposal before Government for higher mark up on medicines;

(c) whether such a proposal has been made on any factual data or study;

(d) if so, what are the details thereof;

(e) whether it is a fact that the profitability of drug companies is one of the highest in this country;

(f) whether it is also a fact that number of instances of overcharging making unintended benefits and marketing without price approval of drug companies have come to Government's notice; and

(g) if so, what is the justification for allowing higher mark up?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) to (d) and (g) Government has not yet finalised their views on New Drug Policy.

(e) No, Sir.

(f) Several instances of the type referred to have come to the notice of the Government and action is being taken on these cases.

Overcharging and T.B. drugs

2184. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 189 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that Isokin Liquid contains Isoniazide 50 mg per 5 ml and Isokin-300 contains Isoniazide 300 mg per tablet;

(b) whether it is a fact that Isoniazide is covered under category I of Drugs Price Control Order, 1979;

(c) whether it is fact that these are anti TB medicines;

(d) whether it is a fact that to provide anti-TB medicines to poor TB patients at cheap prices is one of our 20-Point Programmes;

(e) whether it is also a fact that since 1979, Warner Hindustan had been overcharging the poor TB patients; and

(f) if so, on what basis their overcharging activity has been regularised without any penal action as provided under provision 29 of Drugs Price Control Order, 1979?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Isokin Liquid contains Isoniazid 50 mg. per 5 ml. but, Isokin 300 tablets contain INH 300 mg|tablet and Vitamin B6 10 mg per tablet.

(b) Bulk drug Isoniazid is specified under Category I in the First Schedule to the Drugs (Prices Control) Orer, 1979.

(c) and (d) yes, Sir.

(e) and (f) Position has already been explained in reply to Rajya Sabha Starred Question No. 19 answered on 18th November, 1985.

Price control to cover all drugs

2185. SHRI (MOLANA) ASRARUL HAQ: Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news item captioned